Loading
A phase 2 trial of Cemiplimab in non-small-cell lung cancer and small-cell lung cancer, run by Regeneron Pharmaceuticals, active and no longer recruiting.
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) is a phase 2 interventional study registered as NCT06465329 by Regeneron Pharmaceuticals, with 120 participants planned, started 2024-11-18 and due to reach its primary completion in 2027-05-20. Interventions recorded: Cemiplimab, Platinum-based chemotherapy, REGN7075. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Regeneron, Cemiplimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares REGN7075, Regeneron, Cemiplimab, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Resectable stage I to III non-small-cell lung cancer, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Resectable stage I to III non-small-cell lung cancer, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Small-cell lung cancer, Immune checkpoint inhibitors.
Shares Regeneron, Cemiplimab, Resectable stage I to III non-small-cell lung cancer, Small-cell lung cancer.
Shares Regeneron, Cemiplimab, Resectable stage I to III non-small-cell lung cancer, Immune checkpoint inhibitors.
Shares REGN7075, Regeneron, Cemiplimab, Immune checkpoint inhibitors.